Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adverum Biotechnologies, Inc.ADVM · Entity 71889 | SVP, Clinical Development | February 09, 2017 | February 13, 2017 |
| Disc Medicine, Inc.GMTX · Entity 2273 | Chief Medical Officer | April 12, 2021 | April 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adverum Biotechnologies, Inc.
Report date February 09, 2017 · Filed February 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 172,335 |
Reported balance
After 2017-02-09 transaction · row 1
1 source rowRow 1 · 2017-02-09 · Grant · Acquired 58,000 · Balance 172,335 F1: Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock of the Issuer for each one (1) RSU upon the vesting thereof. Such RSUs vest with respect to 25% of the shares subject thereto on each anniversary of February 9, 2017 (the "Vesting Commencement Date"), such that all of the shares subject to the RSUs shall be vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2027-02-08 | Direct | 84,000 |
Reported balance
After 2017-02-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-02-09 · Grant · Acquired 84,000 · Balance 84,000 F2: Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of the Vesting Commencement Date, and 1/48th of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock of the Issuer for each one (1) RSU upon the vesting thereof. Such RSUs vest with respect to 25% of the shares subject thereto on each anniversary of February 9, 2017 (the "Vesting Commencement Date"), such that all of the shares subject to the RSUs shall be vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F2: Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of the Vesting Commencement Date, and 1/48th of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
Disc Medicine, Inc.
Report date April 12, 2021 · Filed April 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.59 · Expires 2031-04-11 | Direct | 255,212 |
Reported balance
After 2021-04-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-12 · Grant · Acquired 255,212 · Balance 255,212 F1: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, April 12, 2021, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, April 12, 2021, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 12, 2021 Filed Apr 14, 2021 20:03 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 255,212 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0001213900-21-021520 · ownership.xml · derivative · entry 1 Barone Samuel B. · CIK 0001614995 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,212 Underlying: Common Stock · 255,212 shares Expires 2031-04-11 F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, April 12, 2021, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 17:35 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | GrantStock Option (Right to Buy) · Derivative | 84,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-17-010103 · doc4.xml · derivative · entry 2 Barone Samuel B. · CIK 0001614995 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,000 Underlying: Common Stock · 84,000 shares Expires 2027-02-08 F2 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of the Vesting Commencement Date, and 1/48th of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 17:35 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | GrantCommon Stock | 58,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-010103 · doc4.xml · nonDerivative · entry 1 Barone Samuel B. · CIK 0001614995 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,335 F1 · shares: Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock of the Issuer for each one (1) RSU upon the vesting thereof. Such RSUs vest with respect to 25% of the shares subject thereto on each anniversary of February 9, 2017 (the "Vesting Commencement Date"), such that all of the shares subject to the RSUs shall be vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.